Personalis, Inc. (NASDAQ: PSNL) today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place in Boston, MA, November 17-20, including poster presentations on November 18th and 19th.
The company will showcase ImmunoID NeXT™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Following is a list of abstracts that will be presented at the meeting.
Scientific Poster Presentations
Title & Presenter
Day & Time
HLA allele-specific loss of heterozygosity detection
using augmented exome capture approach
Presenter: Rachel Marty Pyke, Ph.D.
12:30 PM – 3:00 PM
Exome scale liquid biopsy monitoring of putative
neoantigens and genomic biomarkers in patients
on anti-PD-1 therapy in squamous cell carcinoma of
the head and neck
Presenter: Charles Abbott, Ph.D.
4:30 PM – 7:00 PM
Personalis will also be exhibiting during the conference (Exhibit # 10). Representatives will be available to answer questions about the company's cancer immunogenomics services.